Antigen-specific depletion of gluten-reactive T cells for the potential treatment of celiac disease 2257650
The Journal of Immunology · 01.08.2026 · 215 (Supplement_1)
DOI: 10.1093/jimmun/vkag141.470 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Immunology, online erschienen am 28.07.2026. Verfasst von Kaitlin Read und 4 weiteren Autor:innen.
Abstract (Originalsprache)
Introduction
Celiac disease (CeD) is a gluten-triggered chronic inflammatory disease of the small intestine that affects roughly 1.4% of the global population. As a strict gluten-free diet is the only treatment option, the development of novel treatment strategies is necessary to alleviate physical, psychological, and financial burdens associated with CeD. Roughly 95% of CeD patients express the MHCII variant HLA-DQ2.5. In susceptible individuals, pathogenesis is mediated by gluten-specific CD4+ T cell populations, which are activated upon presentation of gluten peptides by HLA-DQ molecules. This homogeneity presents the opportunity to design HLA-DQ2.5-based therapies to target pathogenic T cell populations for the elimination of celiac disease.
Methods
As a potential treatment modality, we have engineered human T cells expressing novel ‘chimeric, antigen-presenting’ (CAP) constructs consisting of 1) a gluten peptide-linked HLA-DQ2.5 extracellular domain 2) intracellular CD28/CD3z signaling domains routinely utilized in CAR T cell applications, and 3) an engineered “di-sulfide trap” to stabilize peptide:HLA interactions and CAP surface expression. We hypothesize that upon engagement with gluten-reactive T cells, CAP T cells will specifically eliminate gluten-reactive targets, but leave the remainder of the T cell repertoire untouched. To test this hypothesis, we cultured CAP T cells (effectors) with target cells engineered to express patient-derived gluten-reactive T cell receptors.
Results
Strikingly, CAP T cells eliminated >98% of target cells within 48h. This effect was specific, as non-specific targets cultured with CAP T cells remained untouched. Further, CAP T cells were efficient killers: even at an 8:1 target:effector ratio, there was almost complete ablation of targets within 72h.
Conclusion
This work provides a proof-of-concept for CAP T cells, and demonstrates their potential as a novel, T cell-based immunotherapeutic strategy for the treatment of Celiac disease. Funding Source The Colton Consortium for Autoimmunity at the University of Pennsylvania Topic Categories Therapeutic Approaches to Autoimmunity (THER)
Zitieren
APA
Read, K., Shu, J., McCabe, C., Gabrielski, J., & Riley, J. (2026). Antigen-specific depletion of gluten-reactive T cells for the potential treatment of celiac disease 2257650. The Journal of Immunology, 215(Supplement_1). https://doi.org/10.1093/jimmun/vkag141.470
Vancouver
Read K, Shu J, McCabe C, Gabrielski J, Riley J. Antigen-specific depletion of gluten-reactive T cells for the potential treatment of celiac disease 2257650. The Journal of Immunology. 2026;215(Supplement_1). doi:10.1093/jimmun/vkag141.470
BibTeX
@article{Read2026,
author = {Read, Kaitlin and Shu, Jiayi and McCabe, Caitlin and Gabrielski, Justin and Riley, James},
title = {Antigen-specific depletion of gluten-reactive T cells for the potential treatment of celiac disease 2257650},
journal = {The Journal of Immunology},
year = {2026},
volume = {215},
number = {Supplement_1},
doi = {10.1093/jimmun/vkag141.470}
}
EUVIMED